These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 10986062)
1. Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors. Zamboni WC; Egorin MJ; Van Echo DA; Day RS; Meisenberg BR; Brooks SE; Doyle LA; Nemieboka NN; Dobson JM; Tait NS; Tkaczuk KH J Clin Oncol; 2000 Sep; 18(18):3288-94. PubMed ID: 10986062 [TBL] [Abstract][Full Text] [Related]
2. Phase I study of docetaxel and topotecan in patients with solid tumors. Tkaczuk KH; Zamboni WC; Tait NS; Meisenberg BR; Doyle LA; Edelman MJ; Hausner PF; Egorin MJ; Van Echo DA Cancer Chemother Pharmacol; 2000; 46(6):442-8. PubMed ID: 11138457 [TBL] [Abstract][Full Text] [Related]
3. Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies. Posey JA; Wang H; Hamilton J; Delgrosso A; Zhang R; Freda T; Zamboni WC Cancer Chemother Pharmacol; 2005 Aug; 56(2):182-8. PubMed ID: 15838660 [TBL] [Abstract][Full Text] [Related]
4. Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma. Pro B; Fayad L; McLaughlin P; Romaguera J; Hagemeister FB; Rodriguez MA; Goy A; Loyer E; Younes A Leuk Lymphoma; 2006 Mar; 47(3):481-5. PubMed ID: 16396772 [TBL] [Abstract][Full Text] [Related]
5. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. Holmes FA; O'Shaughnessy JA; Vukelja S; Jones SE; Shogan J; Savin M; Glaspy J; Moore M; Meza L; Wiznitzer I; Neumann TA; Hill LR; Liang BC J Clin Oncol; 2002 Feb; 20(3):727-31. PubMed ID: 11821454 [TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic model of topotecan-induced time course of neutropenia. Zamboni WC; D'Argenio DZ; Stewart CF; MacVittie T; Delauter BJ; Farese AM; Potter DM; Kubat NM; Tubergen D; Egorin MJ Clin Cancer Res; 2001 Aug; 7(8):2301-8. PubMed ID: 11489805 [TBL] [Abstract][Full Text] [Related]
8. Phase I study of docetaxel and topotecan in patients with advanced malignancies. Dubey S; Hutson P; Alberti D; Arzoomanian R; Binger K; Volkman J; Feierabend C; Wilding G; Schiller JH J Oncol Pharm Pract; 2005 Dec; 11(4):131-8. PubMed ID: 16595064 [TBL] [Abstract][Full Text] [Related]
9. Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy. Schilder RJ; Gallo JM; Millenson MM; Bookman MA; Weiner LM; Rogatko A; Rogers B; Padavic-Shallers K; Boente M; Rosenblum N; Adams AL; Ciccotto S; Ozols RF J Clin Oncol; 2001 Feb; 19(4):1183-94. PubMed ID: 11181685 [TBL] [Abstract][Full Text] [Related]
10. Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study. Lilenbaum RC; Ratain MJ; Miller AA; Hargis JB; Hollis DR; Rosner GL; O'Brien SM; Brewster L; Green MR; Schilsky RL J Clin Oncol; 1995 Sep; 13(9):2230-7. PubMed ID: 7545219 [TBL] [Abstract][Full Text] [Related]
11. Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer. Murren JR; Anderson S; Fedele J; Pizzorno G; Belliveau D; Zelterman D; Burtness BA; Tocino I; Flynn SD; Beidler D; Cheng YC J Clin Oncol; 1997 Jan; 15(1):148-57. PubMed ID: 8996136 [TBL] [Abstract][Full Text] [Related]
12. Phase I evaluation of docetaxel and topotecan for patients with advanced solid tumors. Tsao AS; Shin DM; Palmer JL; Lee JS; Glisson BS Cancer; 2004 May; 100(10):2240-5. PubMed ID: 15139070 [TBL] [Abstract][Full Text] [Related]
13. Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group trial. Seibel NL; Blaney SM; O'Brien M; Krailo M; Hutchinson R; Mosher RB; Balis FM; Reaman GH Clin Cancer Res; 1999 Apr; 5(4):733-7. PubMed ID: 10213206 [TBL] [Abstract][Full Text] [Related]
14. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study. Miller AA; Hargis JB; Lilenbaum RC; Fields SZ; Rosner GL; Schilsky RL J Clin Oncol; 1994 Dec; 12(12):2743-50. PubMed ID: 7527456 [TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of escalating dose of docetaxel administered with granulocyte colony-stimulating factor support in adult advanced solid tumors. Gonçalves A; Viret F; Ciccolini J; Genre D; Gravis G; Giovanini M; Camerlo J; Catalin J; Maraninchi D; Viens P Clin Cancer Res; 2003 Jan; 9(1):102-8. PubMed ID: 12538457 [TBL] [Abstract][Full Text] [Related]
16. A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors. Rocha Lima CM; Catapano CV; Pacheco D; Sherman CA; Oakhill G; Mushtaq C; Freeman KD; Green MR Cancer; 2004 Jun; 100(12):2671-9. PubMed ID: 15197811 [TBL] [Abstract][Full Text] [Related]
17. Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan. Akhtar S; Beckman RA; Mould DR; Doyle E; Fields SZ; Wright J Cancer Chemother Pharmacol; 2000; 46(3):204-10. PubMed ID: 11021737 [TBL] [Abstract][Full Text] [Related]
18. High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic study. Rowinsky EK; Baker SD; Burks K; O'Reilly S; Donehower RC; Grochow LB Ann Oncol; 1998 Feb; 9(2):173-80. PubMed ID: 9553662 [TBL] [Abstract][Full Text] [Related]
19. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors. Valero V Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):34-6. PubMed ID: 9364540 [TBL] [Abstract][Full Text] [Related]
20. A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer. Cascinu S; Graziano F; Barni S; Labianca R; Comella G; Casaretti R; Frontini L; Catalano V; Baldelli AM; Catalano G Br J Cancer; 2001 Feb; 84(4):470-4. PubMed ID: 11207039 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]